New assay reveals hidden drug-tolerant TB cells

Tuberculosis remains a stubborn disease because the bacteria that cause it, Mycobacterium tuberculosis, can hide and survive inside the body’s immune cells. A key battleground is the macrophage, a white blood cell that engulfs bacteria and applies a range of immune stresses. Researchers led by David G. Russell asked whether laboratory tests used to evaluate how well drugs kill TB bacteria were missing something important: the stresses that bacteria experience inside macrophages. To address that gap, they built an assay that incorporates macrophage immune stresses and then measures how well intracellular Mycobacterium tuberculosis tolerates drug exposure. Rather than studying free-floating bacteria alone, this approach exposes the bacteria to more realistic conditions that mirror the infected host. By doing so, the team was able to detect differences within the bacterial population — distinct sub-populations that react differently to stress and drug treatment. In short, the study shifts the focus from average behavior of bacteria in a test tube to the varied behaviors of bacteria inside immune cells, highlighting complexity that could explain why some infections are persistent or why treatments sometimes fail.

The core of the work was to adapt an assay to include macrophage immune stresses and then apply that assay to intracellular Mycobacterium tuberculosis. In practice, this meant allowing bacteria to reside within macrophages and subjecting them to conditions those host cells impose during infection, before and during drug exposure. The researchers then assessed survival and drug tolerance of the intracellular bacteria, comparing responses across the population. The key finding was that the bacterial population is not uniform: distinct sub-populations emerge in the infected host, and some of these sub-populations show greater tolerance to drug treatment under macrophage-like stresses. By integrating host-derived stresses into the assay, the team was able to reveal tolerant bacteria that conventional assays might miss. This approach makes it possible to measure how intracellular location and immune pressure change the way Mycobacterium tuberculosis responds to drugs, and to map heterogeneity within the infectious population rather than reporting only an average response.

The implications of these findings are practical and immediate. If drug testing only uses standard conditions that ignore macrophage immune stresses, it may underestimate the presence of drug-tolerant sub-populations and overestimate how well a treatment will perform in a real infection. By incorporating macrophage stresses into assays, researchers and drug developers can better predict which compounds will reach and kill the hardest-to-clear bacteria. This could change how candidate drugs are prioritized, how treatment regimens are designed, and how we think about preventing relapse. Clinicians may also benefit from a clearer understanding that treatment failures and long courses of therapy are driven in part by bacterial sub-populations sheltered inside host cells. Overall, the work suggests a path toward more realistic laboratory tests that reflect the infected host environment and a more targeted approach to eliminating persistent TB bacteria.